or
forgot password

A Continuation Study Of PF-3512676 (CPG 7909) Injection In Patients With Metastatic Or Recurrent Malignancies Who Have Stable Disease Or Who Have Responded To Pf-3512676 Injection Therapy


Phase 2
18 Years
N/A
Not Enrolling
Both
Melanoma, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell, Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

A Continuation Study Of PF-3512676 (CPG 7909) Injection In Patients With Metastatic Or Recurrent Malignancies Who Have Stable Disease Or Who Have Responded To Pf-3512676 Injection Therapy


Inclusion Criteria:



Immediate (within 4 weeks) prior completion of a clinical trial of PF-3512676 Injection
alone or in combination with other anti-neoplastic treatment for malignancy.

Exclusion Criteria:

The patient has received any anti-neoplastic therapy since completing a prior trial with
PF-3512676 Injection, or has participated in another clinical trial following
participation in a trial with PF-3512676 Injection.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Adverse Events and DLTs will be evaluated by the Investigator and summarized.

Outcome Time Frame:

indeterminate

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

C016

NCT ID:

NCT00043368

Start Date:

September 2002

Completion Date:

June 2007

Related Keywords:

  • Melanoma
  • Breast Neoplasms
  • Carcinoma, Renal Cell
  • Lymphoma, T-Cell
  • Carcinoma, Non-Small-Cell Lung
  • CPG 7909 continuation study
  • Breast Neoplasms
  • Neoplasms
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Renal Cell
  • Lymphoma
  • Melanoma
  • Lymphoma, T-Cell

Name

Location
Pfizer Investigational Site Blendora, California  91740
Pfizer Investigational Site Detroit, Michigan  48201
Pfizer Investigational Site Springfield, Illinois  62701-1014
Pfizer Investigational Site Clearwater, Florida  33761
Pfizer Investigational Site Carmel, Indiana  46032
Pfizer Investigational Site Asheville, North Carolina  28801
Pfizer Investigational Site Eugene, Oregon  97401
Pfizer Investigational Site Farmington, Connecticut  06030-3805
Pfizer Investigational Site Bristol, Tennessee  37620
Pfizer Investigational Site Olive Branch, Mississippi  38654
Pfizer Investigational Site Livingston, New Jersey  07039